Key Takeaways:
- First-quarter net profit soared 178-fold year-over-year to $227 million.
- Revenue grew 35.5% to $1.513 billion, beating market expectations.
- Shares opened 4.07% higher in Hong Kong on the strong results.
Back
BEONE Medicines Surges 4% After Q1 Profit Skyrockets 178-Fold
BEONE MEDICINES (06160.HK) saw its first-quarter net profit surge 178-fold to $227 million, driving its shares more than 4% higher in Hong Kong trading.
The company reported total revenue of $1.513 billion for the quarter, a 35.5% year-over-year increase that significantly outpaced sector peers, according to a filing with the Hong Kong Stock Exchange on Wednesday.
The dramatic profit jump from the same period last year translated to a basic earnings per share of $0.16. The results prompted immediate investor enthusiasm, with the stock opening at HKD 189.4. Pre-market turnover reached HKD 41.3 million from 224,700 shares traded. The report also noted significant short-selling interest, with a ratio of 19.736% as of the previous day's close.
BEONE's exceptional growth contrasts with a more challenging quarter for some international healthcare peers, suggesting a strong competitive position. For instance, U.S.-based biote (BTMD) recently reported an 8.3% revenue decrease due to product recall issues. The 178-fold profit increase for BEONE will likely lead to a significant re-evaluation of the company's valuation and focus attention on its upcoming full-year guidance.
The performance highlights a divergence within the global pharmaceutical and health services industry. While CVS Health (CVS) showed strength in its insurance unit, its health services segment saw profit declines. BEONE's results indicate robust demand and operational success in its specific markets.
Investors will now look for whether the company can sustain this momentum. The next catalyst will be the company's second-quarter report and any updates to its full-year forecast.
This article is for informational purposes only and does not constitute investment advice.
[1] BEONE MEDICINES Opens 4.07% Higher as 1Q NP Surges 178x[2] Biote (BTMD) Q1 2026 Earnings Call Transcript[3] CVS Health reports $2.9B in Q1 profit as Aetna strengthens[4] BillionToOne (BLLN) reports Q1 earnings: What key metrics have to say[5] BeOne projects 2026 revenue of $6.3B-$6.5B as it raises guidance by $100M
